• Tankyrase Inhibition Suppresses HCC Growth via Hippo Pathway

  2026-04-30

  Jia et al. (2017) demonstrate that the selective tankyrase 1/2 inhibitor G007-LK suppresses hepatocellular carcinoma (HCC) cell proliferation by modulating the Hippo signaling cascade. This work uncovers a mechanistic link between tankyrase activity, YAP regulation, and HCC cell growth, providing a robust rationale for using tankyrase inhibitors in liver cancer research.

• DOT1L Inhibition Reprograms Immunity in Multiple Myeloma

  2026-04-29

  This study demonstrates that DOT1L inhibition in multiple myeloma (MM) cells reprograms innate immune signaling, activates type I interferon responses, and enhances the efficacy of immunomodulatory drugs like lenalidomide. The findings highlight DOT1L as a promising epigenetic therapeutic target in MM, with mechanistic links to IRG induction and suppression of IRF4-MYC signaling.

• Gamma-linolenic Acid (GLA): Advanced Insights into Anti-infl

  2026-04-29

  Explore the advanced mechanisms and translational implications of Gamma-linolenic acid (GLA) in anti-inflammatory research. This cornerstone article uniquely examines GLA’s biochemical action, clinical relevance, and the interplay with bacterial resistance for precision research decisions.

• DiscoveryProbe Metabolism-related Compound Library: Applied

  2026-04-28

  The DiscoveryProbe™ Metabolism-related Compound Library empowers researchers to dissect metabolic pathways with 493 cell-permeable modulators, accelerating enzyme inhibition, pathway mapping, and disease model studies. This guide delivers actionable protocols, troubleshooting strategies, and real-world workflow enhancements, drawing on recent antiviral research and comparative resources.

• DiscoveryProbe™ Metabolism-related Compound Library: Practic

  2026-04-28

  The DiscoveryProbe™ Metabolism-related Compound Library provides a validated, ready-to-use panel of 493 metabolism-related small molecules for robust in vitro and ex vivo metabolic studies. It is optimized for high-throughput screening, enzyme activity assays, and pathway elucidation, but is not intended for clinical or diagnostic use. Researchers benefit from pre-dissolved, quality-controlled compounds, minimizing variability in metabolic enzyme inhibition and pathway modulation assays.

• EZH2 Inhibition as a Therapeutic Strategy in HPV-Driven Cerv

  2026-04-27

  This study demonstrates that EZH2 inhibitors, particularly EPZ-6438, induce apoptosis and cell cycle arrest in HPV-associated cervical cancer cells, downregulating key oncogenic drivers while upregulating tumor suppressor pathways. The findings provide mechanistic and preclinical evidence supporting the use of selective EZH2 inhibition as a targeted approach in epigenetic cancer research.

• Propranolol Modulates Metabolic Pathways After Severe Burn I

  2026-04-27

  This randomized controlled trial demonstrates that propranolol treatment in severely burned patients significantly normalizes metabolomic and lipidomic signatures in adipose tissue, shifting the metabolic profile toward an anti-inflammatory phenotype. The findings clarify the molecular mechanisms underlying propranolol’s clinical benefits and offer a framework for future metabolic intervention strategies.

• Acetylcysteine: Advancing Translational Models for Chemoresi

  2026-04-26

  Explore how Acetylcysteine (N-acetyl-L-cysteine) is redefining translational research in 3D tumor-stroma modeling. This thought-leadership article dissects the mechanistic basis for oxidative stress modulation, reviews recent advances in personalized organoid-fibroblast co-cultures, and delivers actionable guidance for researchers seeking competitive, reproducible, and clinically relevant workflows. With reference to landmark studies and practical protocols, we position APExBIO’s Acetylcysteine as a strategic tool at the frontier of chemoresistance and redox biology research.

• Belinostat (PXD101) in Cancer Research: Protocols & Pitfalls

  2026-04-25

  Belinostat (PXD101) empowers precise HDAC inhibition for advanced epigenetic cancer research, offering reproducible results in both proliferation and cytotoxicity assays. This guide translates bench breakthroughs and in vitro best practices into actionable workflows, troubleshooting, and comparative insights for bladder and prostate cancer models.

• GSK J4 HCl: Translating JMJD3 Inhibition to Immune Modulatio

  2026-04-24

  Explore how GSK J4 HCl, a potent JMJD3 inhibitor, uniquely advances immune regulation and assay design in epigenetic research. This article bridges mechanistic insight, recent discoveries, and practical protocols for breakthrough applications.

• Nicotinamide Riboside Chloride: Redefining Translational Mod

  2026-04-24

  Explore how Nicotinamide Riboside Chloride (NIAGEN) is advancing precision in metabolic and neurodegenerative disease modeling, with a focus on mechanistic insight, rigorous protocol guidance, and strategic recommendations for translational researchers. This article uniquely bridges foundational NAD+ biology with actionable strategies for improving iPSC-derived retinal ganglion cell and Alzheimer’s disease workflows.

• IWP-2: Wnt Production Inhibitor Workflows for Cancer Researc

  2026-04-23

  IWP-2, a highly potent Wnt production inhibitor from APExBIO, enables precise manipulation of the Wnt/β-catenin pathway in cancer and neurodevelopmental models. This article delivers stepwise protocols, troubleshooting guidance, and evidence-backed insights to optimize experimental outcomes across proliferation, apoptosis, and migration assays.

• Nascent Cone Precursors as the Cell-of-Origin in Human Retin

  2026-04-23

  This study uses longitudinal single-cell analysis of RB1-deficient human retinal organoids to pinpoint ATOH7+ nascent cone precursors as the earliest cell-of-origin of retinoblastoma. The findings clarify the temporal and cellular mechanisms underlying tumor initiation, offering a foundation for targeted therapeutic research.

• VX-702: Precision p38α MAPK Inhibition for Translational Res

  2026-04-22

  Explore how VX-702, a selective p38α MAPK inhibitor, is transforming translational research with novel conformational targeting and cytokine modulation. Discover unique mechanistic insights and protocol guidance not found in existing literature.

• Oxaliplatin in Translational Oncology: Workflow, Assay, and

  2026-04-22

  Oxaliplatin, a platinum-based chemotherapeutic agent, is driving advances in preclinical cancer modeling and personalized drug screening. This article provides actionable workflows, troubleshooting guidance, and a blueprint for leveraging assembloid models to enhance the translational impact of Oxaliplatin-based research.

15710 records 1/1048 page Next 12345 下5页 Last page